Future studies will be needed to demonstrate the causation and disease modification with the immunomodulating therapies, such as with the anti-TNFα monoclonal antibody infliximab, that has already shown promise in the treatment of extracranial aneurysms for the patients with polyarteritis nodosa (36–38). The gene discussed is TNF; the disease is polyarteritis nodosa.